CA Patent

CA2333726A1 — Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis

Assigned to Astex Pharmaceuticals Inc · Expires 1999-12-09 · 26y expired

What this patent protects

Disclosed are methods of treating rheumatoid arthritis by coadministering pentostatin and methotrexate to a host in need thereof, and kits and compositions that include pentostatin and methotrexate.

USPTO Abstract

Disclosed are methods of treating rheumatoid arthritis by coadministering pentostatin and methotrexate to a host in need thereof, and kits and compositions that include pentostatin and methotrexate.

Drugs covered by this patent

testosterone-enanthate (TESTOSTERONE ENANTHATE)

Patent Metadata

Patent number: CA2333726A1
Jurisdiction: CA
Classification: —
Expires: 1999-12-09
Drug substance claim: No
Drug product claim: No
Assignee: Astex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.